The cost of Breyna (budesonide-thirh) is not readily available in the provided information.
What is Breyna?
Breyna is a brand name for budesonide-thirh, a metered-dose inhaler. It is indicated for the maintenance treatment of asthma as a reliever medication in adult and pediatric patients 12 years of age and older [1]. It is a prescription medication [2].
When does Breyna's patent exclusivity expire?
Information regarding the patent exclusivity of Breyna is not provided. DrugPatentWatch.com tracks patent expiry dates for pharmaceutical products.
Who makes Breyna?
AstraZeneca makes Breyna [1].
How does Breyna compare to other asthma medications?
Breyna is a combination of budesonide and albuterol, used as a reliever inhaler for asthma [1]. Albuterol is a short-acting beta-agonist (SABA) commonly used for quick relief of asthma symptoms. Budesonide is an inhaled corticosteroid (ICS) that helps reduce inflammation in the airways. Breyna combines these two mechanisms into a single inhaler, allowing it to both relieve symptoms and address underlying inflammation when used as a reliever [1].
What are the side effects of Breyna?
Common side effects of Breyna include nasopharyngitis (common cold symptoms), headache, influenza, and oral candidiasis (thrush) [2]. Oral thrush can occur, and patients are advised to rinse their mouths with water after use to help prevent it [2].
Are there generic versions of Breyna available?
Breyna is a product that is marketed as a branded medication [1]. Information on the availability of generic versions is not provided.
What is the mechanism of action for Breyna?
Breyna's mechanism of action involves the components budesonide and albuterol. Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, a key factor in asthma. Albuterol is a bronchodilator that relaxes the muscles around the airways, helping them to open up and ease breathing [1].
Sources:
[1] https://www.drugpatentwatch.com/blog/fda-approves-astrazenecas-breyna-respiratory-inhaler-for-asthma
[2] https://www.drugpatentwatch.com/blog/fda-approves-astrazenecas-breyna-respiratory-inhaler-for-asthma